| Name | Title | Contact Details |
|---|
Parker Health is a Mexican American founded company; a powerful global agent of change, driven by minority-led leadership, diversity, and innovation. Our mission is resolute: to advance healthcare and technology into the next century by simplifying complexities and realizing the potential of digital health innovation. At the core of our approach is the groundbreaking Parker EHR – a revolutionary Electronic Health Records Management System™ that redefines interoperability, accessibility, and compliance. This innovation empowers patients, healthcare providers, systems, governments, researchers, and payors through a seamless cloud-based architecture that harmonizes patient-centric data, diagnostics, outcomes, care protocols, practitioner engagement, and more. Headquartered in Washington, DC, Parker Health signifies a global catalyst for transformation, rewriting the rules of healthcare through innovative solutions that forge a brighter future.
Image Stream Medical is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Littleton, MA. To find more information about Image Stream Medical, please visit www.imagestreammedical.com
KidsHealth is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
ODC Pharma is a Woodbury, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."